The impact of Artificial Intelligence in the pharmaceutical industry

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new drugs. By leveraging machine learning algorithms, data analytics, and predictive modelling, AI offers unprecedented opportunities for efficiency, precision, and cost-effectiveness in the drug discovery process. In this article, we will explore the current state of the Artificial Intelligence in Drug Discovery Market, its key players, applications, challenges, and the potential impact on the future of healthcare.

Traditional drug discovery is a complex and lengthy process that involves the identification of potential therapeutic compounds, followed by preclinical and clinical testing before reaching the market. This process typically takes many years and involves significant financial investments. However, despite these efforts, the success rate of bringing a new drug to market remains low, with high rates of failure during clinical trials. This inefficiency has prompted the pharmaceutical industry to seek innovative solutions, and AI has emerged as a game-changer.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg receives US patent for Immunomodulator development

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the